DE69222847T2 - Verfahren zur herstellung einer festen dispersion - Google Patents

Verfahren zur herstellung einer festen dispersion

Info

Publication number
DE69222847T2
DE69222847T2 DE69222847T DE69222847T DE69222847T2 DE 69222847 T2 DE69222847 T2 DE 69222847T2 DE 69222847 T DE69222847 T DE 69222847T DE 69222847 T DE69222847 T DE 69222847T DE 69222847 T2 DE69222847 T2 DE 69222847T2
Authority
DE
Germany
Prior art keywords
solid dispersion
producing
chemicals
twin
dissolving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69222847T
Other languages
English (en)
Other versions
DE69222847T3 (de
DE69222847D1 (de
Inventor
Kouichi Nakamichi
Shougo Izumi
Hiroyuki Yasuura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14589572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69222847(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of DE69222847D1 publication Critical patent/DE69222847D1/de
Publication of DE69222847T2 publication Critical patent/DE69222847T2/de
Publication of DE69222847T3 publication Critical patent/DE69222847T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
DE69222847T 1991-04-16 1992-04-14 Verfahren zur herstellung einer festen dispersion Expired - Lifetime DE69222847T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11255491 1991-04-16
JP112554/91 1991-04-16
PCT/JP1992/000470 WO1992018106A1 (en) 1991-04-16 1992-04-14 Method of manufacturing solid dispersion

Publications (3)

Publication Number Publication Date
DE69222847D1 DE69222847D1 (de) 1997-11-27
DE69222847T2 true DE69222847T2 (de) 1998-05-20
DE69222847T3 DE69222847T3 (de) 2005-09-15

Family

ID=14589572

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69222847T Expired - Lifetime DE69222847T3 (de) 1991-04-16 1992-04-14 Verfahren zur herstellung einer festen dispersion

Country Status (12)

Country Link
US (1) US5456923A (de)
EP (1) EP0580860B2 (de)
JP (1) JP2527107B2 (de)
KR (1) KR0182801B1 (de)
AT (1) ATE159426T1 (de)
AU (1) AU1537292A (de)
CA (1) CA2108575C (de)
DE (1) DE69222847T3 (de)
DK (1) DK0580860T4 (de)
ES (1) ES2111065T5 (de)
GR (1) GR3025864T3 (de)
WO (1) WO1992018106A1 (de)

Families Citing this family (271)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
SG43179A1 (en) 1991-12-18 1997-10-17 Warner Lambert Co A process for the prepatation of a solid dispersion
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
ES2145063T3 (es) * 1992-10-14 2000-07-01 Nippon Shinyaku Co Ltd Procedimiento de dislocacion del estado cristalino.
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
DE69332291T2 (de) * 1992-10-16 2003-07-31 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
EP0717988B1 (de) * 1993-08-20 2001-10-17 Nippon Shinyaku Company, Limited Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
DE69432186T2 (de) * 1993-11-18 2004-05-06 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung stabiler arzneimittel
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ATE251896T1 (de) * 1994-12-19 2003-11-15 Daiichi Seiyaku Co Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
ES2199289T3 (es) * 1995-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Dispersion solida de derivados de xantina.
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
HU227745B1 (en) * 1996-05-20 2012-02-28 Janssen Pharmaceutica Nv Antifungal compositions containing itraconazole
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
JPH10114682A (ja) * 1996-10-11 1998-05-06 Shimizu Kagaku Kk グルコマンナン配合持効性内服用薬剤
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
EP1741424B1 (de) 1997-08-11 2018-10-03 Pfizer Products Inc. Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
WO1999034780A1 (de) * 1998-01-12 1999-07-15 Bühler AG Verfahren und vorrichtung zum verkapseln von wirkstoffen
IE980115A1 (en) * 1998-02-16 2000-02-09 Biovail Internat Ltd Solubilizing delivery systems and method of manufacture
BR9911072A (pt) * 1998-05-27 2001-02-06 Euro Celtique Sa Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior
DE19842914A1 (de) * 1998-09-18 2000-03-23 Basf Ag Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
SK285812B6 (sk) * 1998-12-16 2007-08-02 Aventis Pharmaceuticals Inc. Farmaceutická kompozícia obsahujúca antagonistu serotonínového receptora a spôsob jej výroby
DE60039377D1 (de) 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
EP1027886B1 (de) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmazeutische feste Dispersionen
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
MXPA01012170A (es) 1999-05-27 2002-06-21 Euro Celtique Sa Preparacion para la aplicacion de agentes anti-infecciosos y/o anti-inflamatorios para partes externas o internas del cuerpo humano o animal en la remodelacion funcional y cosmetica y tratamientos de reparacion de tejidos.
US7300667B1 (en) 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
DE19949897A1 (de) * 1999-10-15 2001-04-19 Rainer Rogasch Formkörper und Verfahren zu dessen Herstellung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR101216270B1 (ko) 1999-10-29 2012-12-31 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
DE60028754T2 (de) 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
HUP0204372A3 (en) 1999-12-23 2004-06-28 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
RU2277416C2 (ru) * 2000-03-21 2006-06-10 Ниппон Синяку Ко., Лтд. Препараты для перорального введения с замедленным высвобождением
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE10031044A1 (de) 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
AU2001271055B2 (en) * 2000-07-17 2005-07-07 Astellas Pharma Inc. Pharmaceutical composition improved in peroral absorbability
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
DE60143704D1 (de) * 2000-09-25 2011-02-03 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer medizinischen festen dispersion
CA2427815C (en) 2000-10-30 2007-07-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
ITMI20010141A1 (it) * 2001-01-26 2002-07-26 Giuliani Spa Procedimento per la preparazione di composizioni farmaceutiche o dietetiche per la veicolazione nell'intestino di sostanze labili
DE60206889T2 (de) * 2001-02-27 2006-07-27 Astrazeneca Ab Pharmazeutische formulierung enthaltend bicalutamid
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
US6465014B1 (en) * 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
AU2002304387A1 (en) 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
ATE480226T1 (de) * 2001-06-22 2010-09-15 Bend Res Inc Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
EP1269994A3 (de) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
EP1401399A2 (de) * 2001-06-22 2004-03-31 Pfizer Products Inc. Pharmzeutische zubereitungen enthaltend anlagerungsprodukte aus polymer und wirkstoff
EP1404300B1 (de) * 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
US7491407B2 (en) * 2001-10-31 2009-02-17 North Carolina State University Fiber-based nano drug delivery systems (NDDS)
CA2473991C (en) * 2002-02-01 2009-09-15 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
EP1920766B1 (de) 2002-02-01 2017-08-23 Bend Research, Inc Pharmazeutische Zusammensetzungen amorpher Dispersionen von Wirkstoffen und lipophiler mikrophasenbildender Materialien
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
CN1309370C (zh) * 2002-02-01 2007-04-11 辉瑞产品公司 使用改进的喷雾干燥设备制备均匀喷雾干燥的固体非晶形药物分散体的方法
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
ATE442130T1 (de) 2002-08-12 2009-09-15 Bend Res Inc Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
BR0317521A (pt) 2002-12-20 2005-11-16 Pfizer Prod Inc Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa
WO2004069180A2 (en) * 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
US8486447B2 (en) * 2003-02-03 2013-07-16 Novartis Ag Pharmaceutical formulation
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
BRPI0416596A (pt) * 2003-11-14 2007-01-30 Pfizer Prod Inc dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade
BRPI0417492A (pt) * 2003-12-09 2007-05-29 Pfizer composições compreendendo um inibidor de protease de hiv
BRPI0507462A (pt) 2004-02-04 2007-07-10 Pfizer Prod Inc compostos de quinolina substituìdos
US20050238721A1 (en) * 2004-04-07 2005-10-27 Acquarulo Lawrence A Jr One step compounding extrusion of drug filled polymers
US20070237823A1 (en) * 2004-05-04 2007-10-11 Thomas Bock Solid Pharmaceutical Form Comprising and Ltb4 Antagonist
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
DE602005010074D1 (de) * 2004-05-28 2008-11-13 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
US20080213339A1 (en) * 2005-08-02 2008-09-04 Roger Imboden Pharmaceutical Composition Containing Indometacin and/or Acemetacin
US8187639B2 (en) * 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
EP1933852B1 (de) 2005-09-27 2018-12-19 TissueTech, Inc. Amnion-zubereitungen und gereinigte zusammensetzungen und anwendungsverfahren
WO2007062266A2 (en) 2005-11-28 2007-05-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
EP1832281A1 (de) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Verfahren zur Herstellung einer Feststoffdispersion eines aktiven Wirkstoffes
EP2056818B1 (de) 2006-08-11 2011-05-25 The Johns Hopkins University Zusammensetzungen und verfahren für nervenschutz
MX347525B (es) 2006-09-22 2017-04-27 Pharmacyclics Llc Inhibidores de tirosina cinasa de bruton.
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US7607596B1 (en) 2007-03-07 2009-10-27 Exxpharma, LLC Process for enhancing the solubility of poorly soluble drugs
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (de) 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN101754962B (zh) * 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
WO2009026461A2 (en) * 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
WO2009038112A1 (ja) * 2007-09-21 2009-03-26 Shionogi & Co., Ltd. Npyy5受容体拮抗剤を含有する固形製剤
AU2008303129B2 (en) * 2007-09-25 2013-08-01 Formulex Pharma Innovations Ltd. Compositions comprising lipophilic active compounds and method for their preparation
WO2009053635A1 (fr) * 2007-10-11 2009-04-30 L'oreal Composition cosmetique structuree
FR2922100B1 (fr) * 2007-10-11 2009-12-11 Oreal Procede de preparation de particules semi-solides a interet cosmetique
EP2231169B1 (de) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
JP5711655B2 (ja) * 2008-03-31 2015-05-07 シマベイ セラピューティクス, インコーポレーテッド オキシメチレンアリール化合物およびその使用
MX2011002149A (es) 2008-08-27 2011-04-05 Calcimedica Inc Compuestos que modulan el calcio intracelular.
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
EP3023433A1 (de) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Neuartige prodrugs von steroidalen cyp17-hemmern/-antiandrogenen
TWI404719B (zh) 2009-04-03 2013-08-11 Hoffmann La Roche 組合物及其用途
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
WO2010147978A1 (en) 2009-06-16 2010-12-23 Pfizer Inc. Dosage forms of apixaban
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EP2483281B1 (de) * 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituierte tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidinsalze
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
JP5749790B2 (ja) * 2010-03-26 2015-07-15 ダウ グローバル テクノロジーズ エルエルシー 多層溶融押出フィルム
CN103153580A (zh) * 2010-03-26 2013-06-12 陶氏环球技术有限责任公司 制备熔体挤出的膜的方法和熔体挤出的膜
US20110236465A1 (en) * 2010-03-26 2011-09-29 Hall Mark J Melt-extruded film
US20130030237A1 (en) 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
EP2563759B1 (de) 2010-04-27 2022-04-06 Calcimedica, Inc. Verbindungen als modulatoren von intrazellulärem calcium
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
US20130072519A1 (en) 2010-05-21 2013-03-21 Edward Lee Conn 2-phenyl benzoylamides
AU2011261185A1 (en) 2010-06-03 2013-01-10 Pharmacyclics, Inc. The use of inhibitors of Bruton's tyrosine kinase (Btk)
CN103037843A (zh) * 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
AU2011272839B2 (en) 2010-07-02 2015-04-02 The Procter & Gamble Company Methods of delivering a health care active by administering personal health care articles comprising a filament
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2012109075A1 (en) 2011-02-07 2012-08-16 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX2013008476A (es) 2011-02-17 2013-08-12 Hoffmann La Roche Proceso para cristalizacion controlada de un ingrediente farmaceutico activo a partir del estado liquido superenfriado por extrusion de fusion en caliente.
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
DE102011015370A1 (de) * 2011-03-29 2012-10-04 Emodys Gmbh Matrix für eine orale Darreichungsform, Verfahren zu deren Herstellung sowie Verwendung derselben
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
EP2717888B1 (de) 2011-06-10 2020-09-09 Tissuetech, Inc. Verfahren zur verarbeitung fötaler gewebesubstrate
KR101774223B1 (ko) 2011-08-18 2017-09-12 닥터 레디스 레보러터리즈 리미티드 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
ES2627820T3 (es) 2011-09-13 2017-07-31 Pharmacyclics, Inc. Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y usos de las mismas
IN2014CN02290A (de) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス,インク. カルバメート化合物およびその製造および使用
IN2012DE00674A (de) 2012-03-07 2015-08-21 Nat Inst Of Pharmaceutical Education And Res Niper
EP2834238B1 (de) 2012-04-06 2017-02-01 Pfizer Inc. Diacylglycerol-acyltransferase-2-hemmer
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
UA126959C2 (uk) 2012-06-04 2023-03-01 Фармасайклікс Ллс Фармацевтична композиція, що містить інгібітор тирозинкінази брутона
EP3838293A1 (de) 2012-07-11 2021-06-23 Tissuetech, Inc. Zusammensetzungen mit hc-ha/ptx3-komplexen und verfahren zur verwendung davon
WO2014052914A1 (en) 2012-09-28 2014-04-03 University Of Washington Through Its Center For Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
JP2016503420A (ja) 2012-11-19 2016-02-04 ドクター レディズ ラボラトリーズ リミテッド Cetp阻害剤の薬学的組成物
JP6150518B2 (ja) 2012-12-27 2017-06-21 花王株式会社 ポリフェノール組成物の製造方法
WO2014128564A2 (en) 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
EP4066841A1 (de) 2013-03-14 2022-10-05 University of Maryland, Baltimore Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon
EP2837391B1 (de) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose-Acetat-Succinat zur Verwendung als Heißschmelzextrusionsträger, Heißschmelzextrusionszusammensetzung und Verfahren zur Herstellung eines Heißschmelzextrudats
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US9296882B2 (en) 2013-09-04 2016-03-29 Zzyzx Polymers LLC Methods for increasing throughput rates of solid-state extrusion devices
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20150104508A1 (en) * 2013-10-12 2015-04-16 Zzyzx Polymers LLC Devices, compositions, and methods for fabricating drug delivery systems
EP3077388A1 (de) 2013-12-05 2016-10-12 Pharmacyclics, LLC Hemmer der bruton-tyrosinkinase
WO2015120389A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
CN106535889A (zh) 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
SG11201606779RA (en) 2014-03-17 2016-10-28 Pfizer Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US10894058B2 (en) 2014-08-29 2021-01-19 Kao Corporation Method for producing solid dispersion containing hardly soluble polyphenol
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
CA2964068A1 (en) * 2014-09-19 2016-03-24 Board Of Regents, The University Of Texas System Methods of preparing extrudates
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
EP3253766B1 (de) 2015-02-06 2019-09-04 University of Washington Verbindungen und verfahren zur vorbeugung oder behandlung von sensorischem haarzelltod
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
AU2016225000B2 (en) 2015-02-27 2021-04-01 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
MA41643A (fr) 2015-03-03 2018-01-09 Pharmacyclics Llc Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
SG10202012002TA (en) 2015-05-11 2021-01-28 Lundbeck La Jolla Research Center Inc Methods of treating inflammation or neuropathic pain
TWI720984B (zh) 2015-05-20 2021-03-11 美商帝聖工業公司 用於防止上皮細胞增生及上皮-間質轉移之組合物及方法
CN117547528A (zh) 2015-05-28 2024-02-13 瑞迪博士实验室有限公司 用于治疗疼痛的塞来昔布口服组合物
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (de) 2015-08-07 2018-06-13 Patara Pharma LLC Verfahren zur behandlung von mastzellbedingten erkrankungen mit mastzellstabilisatoren
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340982B1 (de) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Verbindungen zur behandlung von immun- und entzündungserkrankungen
JP2018525411A (ja) 2015-08-31 2018-09-06 ファーマサイクリックス エルエルシー 多発性骨髄腫を治療するためのbtk阻害剤の組み合わせ
AU2016374497B2 (en) 2015-12-16 2022-03-10 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
BR112018014590A2 (pt) 2016-01-19 2018-12-11 Janssen Pharmaceutica Nv formulações/composições compreendendo um inibidor de btk
AU2017208473B2 (en) 2016-01-19 2022-04-21 Janssen Pharmaceutica Nv Formulations/compositions comprising a BTK inhibitor
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
AU2017246334C1 (en) 2016-04-04 2022-11-17 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using Trapidil
AU2017263574B2 (en) 2016-05-12 2022-11-17 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
US11045550B2 (en) 2016-05-13 2021-06-29 Merck Patent Gmbh Use of an amino sugar as plasticizer
KR20230151062A (ko) 2016-05-13 2023-10-31 메르크 파텐트 게엠베하 용융 압출 적용을 위한 중합체의 입자 크기 및 분포
CA3025268A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
EP3448389B1 (de) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Chinazolin- und indolderivate zur behandlung von medizinischen störungen
CA3030821A1 (en) 2016-07-18 2018-01-25 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN109843868A (zh) 2016-08-26 2019-06-04 科泰纳制药公司 Olig2活性的抑制
EP3506893A4 (de) 2016-08-31 2020-01-22 Respivant Sciences GmbH Cromolynzusammensetzungen zur behandlung von chronischem husten aufgrund von idiopathischer pulmonaler fibrose
EP3522983A4 (de) 2016-10-07 2020-06-03 Respivant Sciences GmbH Cromolynzusammensetzung zur behandlung von lungenfibrose
EP3534881A1 (de) 2016-11-07 2019-09-11 Merck Patent GmbH Tablette mit kontrollierter freisetzung auf basis von polyvinylalkohol und deren herstellung
CA3042770A1 (en) 2016-11-07 2018-05-11 Merck Patent Gmbh Anti-alcohol-induced dose dumping tablet based on polyvinyl alcohol
WO2018083113A1 (en) 2016-11-07 2018-05-11 Merck Patent Gmbh Instant release capsule based on hot melt extruded polyvinyl alcohol
BR112019009992A2 (pt) 2016-11-16 2019-08-27 Abide Therapeutics Inc formulações farmacêuticas
RS65016B1 (sr) 2016-11-16 2024-01-31 H Lundbeck As Kristalni oblik magl inhibitora
CA3056030A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
CN115093337A (zh) * 2017-08-01 2022-09-23 浙江普利药业有限公司 一种马来酸曲美布汀晶型及其制备方法
US11779573B2 (en) 2017-09-01 2023-10-10 University Of Washington Crystalline forms of compounds for preventing or treating sensory hair cell death
WO2019094434A1 (en) 2017-11-07 2019-05-16 The Regents Of The University Of Michigan Therapeutic combination for treatment of cerebellar ataxia
CA3082077A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l degraders and methods of treatment therewith
CA3084809A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
CN112533581A (zh) 2018-06-07 2021-03-19 密歇根大学董事会 Prc1抑制剂及用其进行治疗的方法
TW202019887A (zh) 2018-07-27 2020-06-01 美商同心止痛劑股份有限公司 酚系trpv1促效劑之聚乙二醇化前藥
US20200069742A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
MX2021002428A (es) 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
EP3866773A4 (de) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Kohlenmonoxid-prodrugs zur behandlung von erkrankungen
US10925904B2 (en) 2018-11-06 2021-02-23 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
AU2019417833A1 (en) 2018-12-31 2021-06-24 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
US11833186B2 (en) 2019-02-01 2023-12-05 Myos Corp. Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
WO2020190890A1 (en) 2019-03-15 2020-09-24 Unicycive Therapeutics Inc. Nicorandil derivatives
WO2020210205A1 (en) * 2019-04-08 2020-10-15 Cosci Med-Tech Co., Ltd Methods of improving pharmaceutical substance solubilization and products thereof
CA3136880C (en) 2019-04-19 2023-09-19 Pfizer Inc. Anti-proliferative agents for treating pah
CN113874019A (zh) 2019-05-20 2021-12-31 辉瑞大药厂 用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
EP3990452A1 (de) 2019-06-28 2022-05-04 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazolderivate als bckdk-inhibitoren zur behandlung verschiedener erkrankungen
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶2 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Nafld/nashおよび関連疾患の処置のための組合せ
US11702393B2 (en) 2020-04-21 2023-07-18 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
AU2021289169B2 (en) 2020-06-09 2024-01-04 Pfizer Inc. Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
EP4263542A1 (de) 2020-12-16 2023-10-25 Biomea Fusion, Inc. Kondensierte pyrimidinverbindungen als inhibitoren der menin-mll-interaktion
CA3204457A1 (en) 2021-01-06 2022-07-14 Ben SESSA Mdma in the treatment of alcohol use disorder
WO2022238507A1 (en) 2021-05-11 2022-11-17 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions
US20230120115A1 (en) 2021-08-11 2023-04-20 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
CA3229150A1 (en) 2021-08-20 2023-02-23 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cance
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
TW202337429A (zh) 2021-12-01 2023-10-01 美商輝瑞股份有限公司 支鏈酮酸脫氫酶激酶(bckdk)抑制劑及/或降解劑
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20240010649A1 (en) 2022-07-06 2024-01-11 Oppilan Pharma Limited Crystalline forms of an s1p receptor modulator

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5257315A (en) * 1975-11-04 1977-05-11 Sandoz Ag Tablet for medical preparation
DE2549740A1 (de) * 1975-11-17 1977-05-18 Sandoz Ag Neue galenische formen und verfahren zu deren herstellung
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
JPS5785316A (en) * 1980-11-14 1982-05-28 Kanebo Ltd Preparation of easily absorbable nifedipine preparation
JPS58109411A (ja) * 1981-12-23 1983-06-29 Shionogi & Co Ltd ニフエジピン固型製剤組成物
JPS6240277A (ja) * 1985-08-15 1987-02-21 Ajinomoto Co Inc 顆粒状食品の製造法
US4778676A (en) * 1985-12-20 1988-10-18 Warner-Lambert Company Confectionery delivery system for actives
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US4760094A (en) * 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4842761A (en) * 1988-03-23 1989-06-27 International Flavors & Fragrances, Inc. Compositions and methods for controlled release of fragrance-bearing substances
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3827061C1 (de) * 1988-08-10 1990-02-15 Deutsche Gelatine-Fabriken Stoess & Co Gmbh, 6930 Eberbach, De
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
AU645003B2 (en) * 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
FR2670398B1 (fr) * 1990-12-14 1995-02-17 Roquette Freres Composition pulverulente directement compressible et procede d'obtention.
SG43179A1 (en) * 1991-12-18 1997-10-17 Warner Lambert Co A process for the prepatation of a solid dispersion
DE69332291T2 (de) * 1992-10-16 2003-07-31 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
DE69535433T2 (de) * 1994-09-21 2007-06-28 Kanegafuchi Kagaku Kogyo K.K. Verwendung eines Adsorptionsmittels für Interleukine, Verfahren zu deren Entfernung
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
US5954175A (en) * 1997-09-02 1999-09-21 Northrop Grumman Corporation Modularized parallel drivetrain
AU9587198A (en) * 1997-10-07 1999-04-27 Fuisz Technologies Ltd. Immediate release drug delivery forms
US6029764A (en) * 1997-11-12 2000-02-29 Case Corporation Coordinated control of an active suspension system for a work vehicle
DE60039377D1 (de) * 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
EP1027886B1 (de) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmazeutische feste Dispersionen
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten

Also Published As

Publication number Publication date
EP0580860B2 (de) 2004-12-15
DK0580860T4 (da) 2005-03-21
ES2111065T5 (es) 2005-06-16
GR3025864T3 (en) 1998-04-30
JP2527107B2 (ja) 1996-08-21
CA2108575C (en) 2002-10-22
ES2111065T3 (es) 1998-03-01
US5456923A (en) 1995-10-10
DE69222847T3 (de) 2005-09-15
EP0580860A4 (en) 1994-06-15
DK0580860T3 (da) 1998-05-25
CA2108575A1 (en) 1992-10-17
ATE159426T1 (de) 1997-11-15
KR0182801B1 (ko) 1999-05-01
DE69222847D1 (de) 1997-11-27
EP0580860B1 (de) 1997-10-22
AU1537292A (en) 1992-11-17
EP0580860A1 (de) 1994-02-02
WO1992018106A1 (en) 1992-10-29

Similar Documents

Publication Publication Date Title
ATE159426T1 (de) Verfahren zur herstellung einer festen dispersion
DE59204317D1 (de) Thermoplastische Formmassen aus semikristallinem und amorphem Polyamid, deren Verwendung und Verfahren zu ihrer Herstellung.
DE3887857D1 (de) Orientierte, geschmolzene, geblasene Fasern, Verfahren zur Herstellung derselben und aus diesen Fasern hergestellte Vliese.
DE69935912D1 (de) Artikel mit elastizität bei hoher temperatur hergestellt aus bestrahlten und vernetzten ethylenpolymeren und verfahren zu ihrer herstellung
DE68912825T3 (de) Polypropylen-Zusammensetzung und Verfahren zur Herstellung von Folien aus dieser Zusammensetzung.
BR8902877A (pt) Processo para a producao de compostos estabilizantes uv para polimeros organicos
DE69009658D1 (de) Verfahren zur Herstellung von einem antibakteriellen, geformten Gegenstand aus Polyolefinharz.
DE69012039D1 (de) Poly-hexamethylen-adipamid-Garn mit hoher Festigkeit und niedrigem Schrumpf und Verfahren zur Herstellung desselben.
DE69101495D1 (de) Verfahren zur Herstellung einer ophthalmischen Linse aus Kunststoff und eine so hergestellte ophthalmische Linse.
ATE156165T1 (de) Ölabstossende polymerzusammensetzungen und ihre verwendung zur herstellung von geformten körpern, die mit hoher lösungsmittelstabilität und geringer verschmutzungsneigung ausgestattet sind
DE3750263D1 (de) Vernetzte polypropylenfasern, verfahren zur herstellung und nichtgewobene textilien daraus.
DE3484091D1 (de) Verstrecktes produkt aus kristallinischem polymer mit hoher festigkeit und hohem modul und verfahren zur herstellung desselben.
DE3788188D1 (de) Formgegenstand aus Kunstharz mit ausgezeichneter antistatischer Eigenschaft und Verfahren zu seiner Herstellung.
DE3784788T2 (de) Verfahren zur herstellung von extrudierten produkten aus einer flammhemmenden, vernetzten polyolefin-zusammensetzung.
DE69023797D1 (de) Verfahren zur Herstellung von orientierten geformten Artikeln aus Mischungen von para-Aramid mit thermisch verfestigbaren Polymeren.
ATE13156T1 (de) Verfahren zur herstellung von aus polymeren bestehenden gegenstaenden.
DE69109774D1 (de) Direkt verarbeitbares Polyimid und Verfahren zur Herstellung.
DE69213559T2 (de) Tetravinylpyrazine-Verbindung, Verfahren zur Herstellung derselben und elektrolumineszentes Element und damit hergesteller nichtlinearer optischer Stoff
DE60001724D1 (de) Ein Verfahren zur Herstellung einer Leiter und eine durch dieses Verfahren hergestellte Leiter
AT362926B (de) Verfahren zur herstellung von einachsig gereckten formguetern wie folien, baender, fasern od.dgl. aus polymerem kunststoff
ATE120809T1 (de) Verfahren zur herstellung von monofilen aus einer ternären formmasse auf basis thermoplastischer kunststoffe und hieraus extrudierte monofile.
DE69127931T2 (de) Herstellung von Polymeren aus Kohlenmonoxid mit olefinisch ungesättigten Verbindungen
ATE3654T1 (de) Kontinuierliches verfahren zur herstellung von faeden oder fasern aus schwerloeslichen synthetischen polymeren.
DE59207928D1 (de) Verfahren zur Herstellung von Heterofullerenen und Fullerenen
ATE181694T1 (de) Im kunststoffspritzverfahren hergestelltes kunstoffbauteil

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: HANSMANN & VOGESER, 81369 MUENCHEN

8366 Restricted maintained after opposition proceedings
R071 Expiry of right

Ref document number: 580860

Country of ref document: EP